Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Ipsen's Corabotase Shows Sustained Efficacy and High Patient Satisfaction in Phase II

Ipsen presented positive first-in-class Phase II data for corabotase in moderate-to-severe glabellar lines at the 2026 Scale Symposium. The investigational recombinant neuroinhibitor demonstrated a rapid onset of action of 0.84 days and a statistically significant peak effect superior to placebo. At Week 24, 60.8% of patients treated with corabotase experienced a clinically significant sustained duration of effect, significantly outperforming both placebo (0.2%) and Dysport (36.7%). These strong efficacy results were further supported by high patient satisfaction scores, with 82.8% of patients reporting being "very satisfied" or "satisfied" at Week 24.

• The Phase II LANTIC trial demonstrated significant efficacy for corabotase (50ng) in treating glabellar lines. At Week 4, 66% of patients achieved a statistically significant ≥2-grade improvement (composite response) compared to 0% with placebo (p=0.0001). This sustained efficacy was evident at Week 24, where 60.8% of corabotase-treated patients maintained a clinically significant duration of effect, a notable improvement over placebo (0.2%) and Dysport (36.7%).
• Patient-reported outcomes highlighted the positive experience with corabotase, showing a rapid onset of action at just 0.84 days. Furthermore, patient satisfaction was consistently high, with 82.8% of individuals treated with corabotase (50ng) rating themselves as "very satisfied" or "satisfied" on the Subject Level of Satisfaction scale at Week 24. The treatment was also well-tolerated across all evaluated doses, with no significant safety concerns.
• Corabotase (IPN10200) is Ipsen’s first-in-class recombinant neuroinhibitor (RNI™), specifically engineered to optimize receptor affinity, enhance cellular uptake, and improve resistance to degradation, leading to sustained inhibition of neurotransmitter release. Following these promising Phase II results, the 50ng dose has been selected for further evaluation in the upcoming Phase III LAURITE program, with additional proof-of-concept data for other upper facial lines expected later this year from the ongoing LANTIC trial.

Corabotase Phase II Data: Sustained Efficacy and Patient Satisfaction

Recent clinical trials have demonstrated the efficacy and safety of several botulinum toxin formulations for treating moderate-to-severe glabellar lines. A Phase III trial comparing CKDB-501A versus onabotulinumtoxinA in 300 subjects showed that 80.69% of CKDB-501A-treated patients achieved ≥2-point improvement in Facial Wrinkle Scale scores at week 4, compared to 70.83% for onabotulinumtoxinA, confirming non-inferiority. CKDB-501A, which is completely free from animal-derived components including human serum albumin, demonstrated sustained efficacy up to 16 weeks with approximately 70% of patients maintaining at least a 1-point improvement. Both treatments exhibited comparable safety profiles with no adverse events related to local or distant toxin spread, hypersensitivity reactions, or neutralizing antibody formation.

Another notable Phase III study (NCT05364580) evaluated Protoxin, a novel botulinum toxin type A, in 274 subjects through a multicenter, randomized, double-blind, active-controlled design. Patients received 20 units injected at five glabellar sites, with week 4 improvement rates of 62.22% for Protoxin versus 62.96% for onabotulinumtoxinA. The study confirmed non-inferiority as the lower limit of the two-sided 95% confidence interval exceeded the predetermined -15% margin, and safety profiles remained comparable between treatment groups.

A systematic review and meta-analysis of LetibotulinumtoxinA-wlbg encompassing three randomized controlled trials with 1,272 patients revealed significant efficacy advantages over placebo. The composite responder rate at week 4 showed a risk ratio of 59.47 (95% CI: 14.95, 236.52), with sustained efficacy observed at weeks 12 and 16. Treatment resulted in significant improvements in investigator-assessed, subject-assessed, and psychological outcomes, including enhanced patient psychological well-being related to facial appearance. Importantly, no significant increase in serious, non-serious, or overall treatment-emergent adverse events was observed compared to placebo, supporting a favorable safety profile for this formulation.

Unpacking the LANTIC Phase II Trial Design for Corabotase

Recent clinical trials for glabellar line treatments have employed robust phase III designs with standardized assessment methodologies. These studies have consistently utilized randomized, double-blind, placebo-controlled designs with extended follow-up periods to capture both efficacy and safety profiles across multiple botulinum toxin formulations.

• READY-1 study (2024): 3:1 randomized, 6-month, Phase 3, multicenter, double-blind study with RelaBoNT-A (50 U) versus placebo in 297 adults, featuring dual primary endpoints including composite ≥2-grade response and investigator-reported responder rates at Month 1

• SAKURA 1, 2, and 3 studies (2024): Comprehensive Phase 3 program with two randomized, double-blind studies and one open-label trial evaluating DaxibotulinumtoxinA 40 U in 2785 patients, assessing glabellar line severity for ≤36 weeks using IGA-FWS and PFWS scales

• PrabotulinumtoxinA-xvfs pilot study (2023): Phase 2 study with 154 patients randomized 1:1:1 to three dose groups (40 U prabotulinumtoxinA-xvfs, 20 U prabotulinumtoxinA-xvfs, or 20 U onabotulinumtoxinA), utilizing Kaplan-Meier analysis to estimate duration of effect as the primary endpoint

• AboBoNT-A solution Phase III (2022): Multicenter, multinational study (NCT02493946) with 2:1 randomization (50 U versus placebo) followed by open-label period with 4 treatment cycles, including comprehensive FACE-Q patient-reported outcome measures

• AbobotulinumtoxinA dose-escalation study (2021): 36-week multicenter, randomized, dose-ranging study in 399 subjects comparing 50, 75, 100, or 125 U doses versus placebo, with Week 4 composite ≥2-grade responder rate as primary endpoint

• Historical BOTOX study (2002): Foundational randomized, placebo-controlled trial in 264 patients using 20 U intramuscular injections into 5 glabellar sites, establishing 120-day follow-up protocols and physician rating scales for glabellar line severity assessment

Corabotase's Phase II Data Signals a Shift in Aesthetic Treatments

Ipsen's recent presentation of Phase II data for corabotase in glabellar lines represents a compelling development that could significantly influence the future of aesthetic medicine. As a first-in-class recombinant neuroinhibitor, corabotase offers a potentially novel approach to addressing facial lines, distinguishing itself from the well-established botulinum neurotoxins that primarily function by interrupting acetylcholine neurotransmission at the neuromuscular junction. The data highlights two critical advantages: a remarkably rapid onset of action, observed at just 0.84 days, and a significantly extended duration of effect, with 60.8% of patients maintaining clinical significance at Week 24, notably outperforming Dysport.

This combination of speed and longevity, reinforced by high patient satisfaction, positions corabotase as a formidable contender in a highly competitive market. For Ipsen, this success not only validates their investment in recombinant neuroinhibitor technology but also suggests broader potential for this platform in other therapeutic areas where neuroinhibition is beneficial, akin to how baclofen is utilized for spasticity. However, the path forward is not without its challenges. While promising, Phase II results must be rigorously confirmed in larger, pivotal Phase III trials. Furthermore, as a novel agent, the long-term safety profile, including any potential for immunogenicity, will require careful monitoring. The competitive landscape is also poised for a response, with established players likely to innovate or intensify their market strategies. Ultimately, corabotase has the potential to elevate patient expectations and drive further innovation within the aesthetic neurotoxin space.